Demand For A/H1N1 Vaccine Catapults Green Cross Into No. 2 Spot In Korea; Company Ramps Up Biosimilar Pipeline

SEOUL - Of the many local Korean pharmaceutical players, vaccine producer Green Cross was the biggest beneficiary of the A/H1N1 flu pandemic last year as increased demand for its vaccines triggered a remarkable upgrade in its rankings to the second-largest from its previous long-time position of No. 5